secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-06-25T23:59:59+00:00
Accession:  0001193125-24-167962
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Phase 3 trial of ANX005 meets primary endpoint; GBS patients recover faster
--------------------------------------------------------------------------------

- Primary endpoint at Week 8: 2.41-fold higher likelihood of better health state (p=0.0058).
- ANX005 patients walked 31 days earlier and came off ventilation 28 days earlier vs placebo.
- At Week 26, 21.5% of ANX005 patients fully recovered (GBS-DS=0) vs 8.6% on placebo (OR 4.14, p=0.0092).
- Subgroup with North American/European baseline characteristics showed 3x greater likelihood of better health state at Week 8.
- Single infusion generally well-tolerated; safety profile similar to placebo, no increased infections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524167962/0001193125-24-167962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524167962/d822308d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-167962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer